`
`
`
` NDA 208411/S-004
`
`
`
` APPROVAL LETTER
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Adapt Pharma Operations Limited
`
`
` c/o Emergent Biosolutions Canada Inc.
` Attention: Desiree Crisolo
`
`
` Adapt Pharma Regulatory Representative
`
`
` 300 Professional Drive
`
`
` Gaithersburg, MD 20879
`
`
`
`
` Dear Ms. Crisolo:
`
` Please refer to your Supplemental New Drug Application (sNDA) dated April 13, 2020,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` and received April 15, 2020, pursuant to section 505(b)(2) of the Federal Food, Drug,
`
` and Cosmetic Act (FDCA) for NARCAN (naloxone hydrochloride) nasal spray.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` This Prior Approval supplemental new drug application provides for extension of shelf
`
` life for NARCAN Nasal Spray from the current 2-year shelf-life to 3 years and updates to
`
`
`
`
`
`
`
` the labeling.
`
`
` APPROVAL & LABELING
`
`We have completed our review of this supplemental application. It is approved,
`
`
`
`
`
`
`
`
`effective on the date of this letter, for use as recommended in the enclosed agreed-
`
`
`
`
`
`upon labeling text.
`
`
`CONTENT OF LABELING
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the
`
`
`
`
`
`
`
`
`
`
`
`content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using
`
`
`
`
`
`
`
`
`the FDA automated drug registration and listing system (eLIST), as described at
`
`
`
`
`
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm.
`Content of labeling must be identical to the enclosed labeling (text for the prescribing
`
`
`
`
`
`
`information, text for the patient package insert, and instructions for use) with the
`
`
`
`
`
`
`
`
`addition of any labeling changes in pending “Changes Being Effected” (CBE)
`
`
`
`
`
`
`supplements, as well as annual reportable changes not included in the enclosed
`
`
`
`
`
`
`
`
`labeling.
`
`
`Information on submitting SPL files using eLIST may be found in the guidance for
`
`
`
`
`industry titled SPL Standard for Content of Labeling Technical Qs and As at
`
`
`
`
`
`
`
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guida
`nces/UCM072392.pdf.
`
`
`The SPL will be accessible via publicly available labeling repositories.
`
`
`
`
`
`
`
`U.S. Food & Drug Administration
`
` Silver Spring, MD 20993
`
` www.fda.gov
`
`
`
`
`
`
`
`
`
`
`
`
`
` NDA 208411/S-004
`
` Page 2
`
`
`
`
`
` Also within 14 days, amend all pending supplemental applications that include labeling
`
` changes for this NDA, including CBE supplements for which FDA has not yet issued an
`
`
`
`
`
`
` action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format,
`
`
`
`
`
`
`
`
`
`
` that includes the changes approved in this supplemental application, as well as annual
`
`
`
`
`
`
`
`
` reportable changes, and annotate each change. To facilitate review of your submission,
`
`
`
`
`
` provide a highlighted or marked-up copy that shows all changes, as well as a clean
`
`
`
`
`
` Microsoft Word version. The marked-up copy should provide appropriate annotations,
`
`
`
` including supplement number(s) and annual report date(s).
`
`
`
`
`
`
` CARTON AND IMMEDIATE CONTAINER LABELS
`
`Submit final printed carton and immediate container labels that are identical to enclosed
`
`
`
`
`
`carton and immediate container labels, as soon as they are available, but no more than
`
`
`
`
`
`
`
`30 days after they are printed. Please submit these labels electronically according to
`
`
`
`
`
`
`
`the guidance for industry Providing Regulatory Submissions in Electronic Format –
`
`
`
`
`
`
`Human Pharmaceutical Product Applications and Related Submissions Using the eCTD
`
`
`
`
`
`Specifications (May 2015, Revision 3). For administrative purposes, designate this
`
`
`
`
`submission “Product Correspondence – Final Printed Carton and Container Labels
`
`
`
`for approved NDA 208411/S-004.” Approval of this submission by FDA is not required
`
`
`
`
`
`
`
`
`
`before the labeling is used.
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`
`
`
`
`set forth under 21 CFR 314.80 and 314.81.
`
`
`
`
`If you have any questions, call Teicher Agosto, Regulatory Business Process Manager,
`
`
`
`
`
`
`
`
`
`
`at (240) 402 - 3777.
`
`
`
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`
`Ramesh Raghavachari, Ph.D.
`
`
`Chief, Branch I
`
`
`Division of Post-Marketing Activities I
`
`Office of Lifecycle Drug Products
`
`
`Office of Pharmaceutical Quality
`
`
`
`Center for Drug Evaluation and Research
`
`
`
`
`
`
`Enclosure(s):
`
`Content of Labeling
`
`
`Carton and Container Labeling
`
`
`
`
`
`U.S. Food & Drug Administration
`
` Silver Spring, MD 20993
`
` www.fda.gov
`
`
`
`
`
`Ramesh
`Raghavachari
`
`Digitally signed by Ramesh Raghavachari
`Date: 8/06/2020 02:30:23PM
`GUID: 502d0913000029f375128b0de8c50020
`
`(
`
`
`
`